OV Precision: Study Examining the Benefit of a Tumor- and Patient-specific Cancer Therapy
Status:
RECRUITING
Trial end date:
2028-09-01
Target enrollment:
Participant gender:
Summary
The long-term goal of this research project is to demonstrate whether HRD negative (HPDneg) patients benefit when additional multi-modal biological tumor information is incorporated into the molecular tumor board (mTB) treatment recommendation process.